Colostrinin

Colostrinin is a milk-derived mixture of small proline-rich polypeptides, not one CLN peptide with a fixed sequence. Small human trials report signals for stabilizing mild-to-moderate Alzheimer’s disease and changing some cognitive measures, but the evidence is old, concentrated in Poland, and not enough to treat this dietary-supplement ingredient as an established therapy.

Key facts

• What it is: a proline-rich polypeptide mixture from ovine or bovine colostrum, with components below 10 kDa.
• Evidence tier: human randomized trials, with a mixed verdict.
• U.S. status (2026): sold in oral supplements; not an FDA-approved drug.
• Study doses: 100 micrograms on alternate days in older Alzheimer’s trials; 120 micrograms daily in the 2023 healthy-adult trial.
• Main safety gap: small trials cannot define uncommon reactions, interactions, or long-term risk.
• Sport: USADA warns that colostrum-derived products can contain detectable IGF-1 and are used at the athlete’s own risk.

What is colostrinin?

Colostrinin is a natural complex of low-molecular-weight peptides extracted from the first milk produced after birth. The 2023 paper describes bovine PRP colostrum peptides ranging up to 10 kDa; earlier clinical work used an ovine preparation. That makes “CLN peptide” convenient shorthand, but chemically wrong: this is a crowd of peptides, not one molecule wearing a name tag.

That distinction matters. A mixture has no single amino-acid sequence, molecular formula, molecular weight, or defensible CAS number. Different extraction methods and animal sources may produce different peptide profiles. Colostrinin therefore belongs primarily with immune peptides, with nootropic research as a secondary story. For the broader food context, see what foods contain peptides.

How does colostrinin work?

Colostrinin appears to adjust immune signaling rather than hit one confirmed receptor. The earliest human paper described cytokine-like activity, including induction of interferon-gamma and other cytokines in leukocyte cultures. Later laboratory work explored oxidative stress, amyloid aggregation, and cell-survival pathways, but those mechanisms do not prove that an oral colostrinin supplement changes Alzheimer’s disease in people.

The 2023 trial added a nootropic hypothesis: serum brain-derived neurotrophic factor (BDNF), a protein involved in neuronal growth and plasticity, increased across the study groups. BDNF is a biomarker, not a memory score. Think of it as a dashboard light that may reflect activity in a relevant system; it does not tell you by itself whether the car arrived anywhere useful.

What does the human research show?

Colostrinin has human randomized evidence, but the honest grade is mixed because the trials are small, old, and not broadly replicated. The 1999 double-blind trial randomized 46 people with Alzheimer’s disease among colostrinin, selenium, and placebo. Eight of 15 colostrinin patients improved and seven stabilized, while none in the two comparison groups improved. That is a signal, not a final answer: only 15 people received the active preparation.

The 2002 long-term report followed 33 patients for 16 months, including 13 who had already received it for a year. It reported slight improvement or stabilization, but without a concurrent placebo group the study cannot separate treatment from selection, measurement drift, or the course of disease.

A 2004 multicenter study enrolled 105 patients and compared colostrinin with placebo for 15 weeks before an open-label phase. Cognitive scores and daily function favored colostrinin in the full-sample analysis. Useful, yes; decisive, no. The early program came largely from Polish research centers and has not been followed by the kind of large, independent trial expected for an Alzheimer’s treatment.

The 2023 BDNF RCT randomized 361 healthy adults across three age bands. Results moved in different directions across age groups and cognitive tests, while some comparisons missed conventional statistical significance. The sponsor, Geo-Poland, financed the study; two authors worked for the company, and one author co-owned a related patent. Those facts do not erase the results. They do make independent replication the next useful step.

Does colostrinin help Alzheimer’s disease?

Colostrinin has produced encouraging Alzheimer’s signals, but it has not been established as a treatment. The 46-person trial and the later 105-person study both reported benefits on at least some outcomes. Neither supplies the scale, modern trial design, independent replication, or current standard-of-care comparison needed to conclude that a colostrinin supplement slows Alzheimer’s disease.

This is where evidence labels earn their keep. “Human RCT” describes the study design, not the size or certainty of the answer. The evidence-grading guide explains why a small randomized trial can sit on a high rung while still leaving a wide confidence gap.

Is colostrinin safe? Side effects

Colostrinin looked reasonably well tolerated in the available trials, but the safety database is small. The 1999 Alzheimer’s study reported mild, temporary anxiety, stimulation, insomnia, and tiredness. The 2002 follow-up reported brief anxiety, increased talking, and insomnia. In the 2023 trial, no participants receiving the preparation reported adverse effects.

Those results do not map rare events or long-term interactions. Products are milk-derived, so anyone with a milk allergy has a separate label-reading problem, and supplement batches may differ from the preparations used in trials. “Natural” describes the source. It does not perform quality control.

Is colostrinin FDA-approved or legal in 2026?

Colostrinin is not an FDA-approved drug in the United States; oral products are marketed in the dietary-supplement channel. FDA does not approve dietary supplements for safety or effectiveness before sale. A colostrinin supplement therefore cannot borrow the Alzheimer’s language of a drug label, and disease-treatment claims can cause a product to be regulated as a drug.

For athletes, the molecule is not the only question. USADA warns that colostrum can contain detectable quantities of prohibited IGF-1 and says these animal-derived products are used at the athlete’s own risk. That is not the same as saying purified colostrinin is named on the 2026 prohibited list; it is a product-content warning.

How was colostrinin used in studies?

Colostrinin was taken orally in tablets or lozenges, with study schedules designed around breaks. The 1999 and 2004 Alzheimer’s trials used 100 micrograms every other day for three weeks, followed by two weeks off. The 2023 healthy-adult trial used a 120-microgram lozenge daily for four months, with a 14-day break after each 30-day cycle.

Those are reported research doses, not a personal protocol. More importantly, a retail PRP colostrum product is not automatically compositionally equivalent to the named trial preparation. The most useful question on a label is not merely “how many micrograms?” but “micrograms of exactly what mixture, measured how?”